# US 2005/0239729 A1 · Substances for preventing and treating autoimmune diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0239729 A1
- Document ID: US20050239729A1
- Status: Published application
- Kind: A1
- Application number: 10/523,655
- Filed: 2003-08-06
- Published: 2005-10-27
- Earliest claimed: 2002-08-06
- Assignees: Loma Linda University
- Inventors: Alan Escher; Fengchun Li
- Web page: https://patentgrep.com/patent/US20050239729A1

## CPC

- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 38/1709: {from mammals}
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/005: from viruses
- C07K 14/4713: {Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens}
- C07K 14/4747: {Apoptosis related proteins}
- C12N 5/00: Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00)
- C12N 15/00: Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (mutants or genetically engineered microorganisms, per se C12N1/00, C12N5/00, C12N7/00; new plants per se A01H; plant reproduction by tissue culture techniques A01H4/00; new animals per se A01K67/00; use of medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases, gene therapy A61K48/00)
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55516: {Proteins; Peptides}
- C12N 2710/10322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2840/203: having an IRES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A substance for preventing, delaying the onset of, or treating one or more than one autoimmune disease, the substance comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for the autoimmune disease. A method for preventing, delaying the onset of or treating an autoimmune disease in a patient comprising selecting a patient who is susceptible to developing the autoimmune disease, who is developing the autoimmune disease or who has the autoimmune disease and administering to the patient one or more than one dose of a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for an autoimmune disease, or comprising a polynucleotide sequence encoding the adenoviral protein E3-GP19k, or comprising a polynucleotide sequence encoding ΔBCL-2.

## Claims

### Claim 1

A substance for preventing, delaying the onset of or treating one or more than one autoimmune disease, the substance comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for the autoimmune disease.

### Claim 2

Use of a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for an autoimmune disease for the manufacture of a medicament for preventing, delaying the onset of or treating the one or more than one autoimmune disease.

### Claim 3

Use of a plasmid comprising a promoter and a polynucleotide sequence encoding only one adenoviral protein, where the only adenoviral protein encoded by the plasmid is E3-GP19k for the manufacture of a medicament for preventing, delaying the onset of or treating one or more than one autoimmune disease.

### Claim 4

Use of a plasmid comprising a promoter and a polynucleotide sequence encoding ΔBCL-2 for the manufacture of a medicament for preventing, delaying the onset of or treating one or more than one autoimmune disease.

### Claim 5 (depends on 2)

Use according to claim 2, where the medicament is manufactured in dosage units of between about 0.5 mg to about 5 mg.

### Claim 6 (depends on 2)

Use according to claim 2, where the medicament is manufactured in dosage units of between about 1 mg to about 4 mg.

### Claim 7 (depends on 2)

Use according to claim 2, where the medicament is manufactured in dosage units of between about 2.5 mg to about 3 mg.

### Claim 8 (depends on 2)

Use according to claim 2, where the medicament is manufactured in a form suitable for intramuscular administration.

### Claim 9 (depends on 2)

Use according to claim 2, where the medicament is manufactured in a form suitable for intravenous administration.

### Claim 10

A method for preventing, delaying the onset of or treating an autoimmune disease in a patient comprising:
a) selecting a patient who is susceptible to developing the autoimmune disease, who is developing the autoimmune disease or who has the autoimmune disease; and
b) administering to the patient one or more than one dose of a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for the autoimmune disease.

### Claim 11 (depends on 10)

The method of claim 10, where the autoimmune disease is type I diabetes.

### Claim 12 (depends on 11)

The method of claim 11, where selecting the patient comprises identifying in the patient the presence of anti-insulin or anti-GAD autoantibodies or both anti-insulin and anti-GAD autoantibodies.

### Claim 13 (depends on 11)

The method of claim 11, where selecting the patient comprises identifying in the patient the presence of increasing hyperglycemia.

### Claim 14 (depends on 11)

The method of claim 11, where selecting the patient comprises identifying in the patient the presence of glycosuria.

### Claim 15 (depends on 10)

The method of claim 10, where selecting the patient comprises identifying in the patient the presence of a genetic predisposition to the autoimmune disease.

### Claim 16 (depends on 10)

The method of claim 10, where the one or more than one dose is a plurality of doses.

### Claim 17 (depends on 10)

The method of claim 10, where administering to the patient one or more than one dose comprises injecting the patient intramuscularly with the one or more than one dose.

### Claim 18 (depends on 10)

The method of claim 10, further comprising, after administering, monitoring the patient for the development the autoimmune disease.

### Claim 19

A method for preventing, delaying the onset of or treating an autoimmune disease in a patient comprising:
a) selecting a patient who is susceptible to developing the autoimmune disease, who is developing the autoimmune disease or who has the autoimmune disease; and
b) inducing an immune response that downregulates a Th1-like immune response in the patient by administering to the patient one or more than one dose of a plasmid comprising a promoter and a polynucleotide sequence encoding only one adenoviral protein, where the only adenoviral protein encoded by the plasmid is E3-GP19k.

### Claim 20 (depends on 19)

The method of claim 19, where administering to the patient one or more than one dose comprises injecting the patient intramuscularly with the one or more than one dose.

### Claim 21

A method for preventing, delaying the onset of or treating an autoimmune disease in a patient comprising:
a) selecting a patient who is susceptible to developing the autoimmune disease, who is developing the autoimmune disease or who has the autoimmune disease; and
b) inducing an immune response that downregulates a Th2-like immune response in the patient by administering to the patient one or more than one dose of a plasmid comprising a promoter and a polynucleotide sequence encoding ΔBCL-2.

### Claim 22 (depends on 21)

The method of claim 21, where administering to the patient one or more than one dose comprises injecting the patient intramuscularly with the one or more than one dose.

### Claim 23

A method for preventing, delaying the onset of or treating an autoimmune disease in a patient comprising:
a) selecting a patient who is susceptible to developing the autoimmune disease, who is developing the autoimmune disease or who has the autoimmune disease; and
b) administering to the patient one or more than one dose of a polynucleotide construct comprising at least two polynucleotide sequences encoding at least two proteins selected from the group consisting of 1) the pro-apoptotic protein BAX and one or more than one autoantigen for the autoimmune disease, 2) the adenoviral protein E3-GP19k, and 3) ΔBCL-2.

### Claim 24 (depends on 23)

The method of claim 23, where administering to the patient one or more than one dose comprises injecting the patient intramuscularly with the one or more than one dose.
